Celularity receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Jan 19, 2027

Celularity Inc

• Received Nasdaq notice on July 23, 2026, for non-compliance with minimum bid price rule (closing bid below $1.00 for 30 consecutive business days).
• Has 180 calendar days, until January 19, 2027, to regain compliance by closing bid price >= $1.00 for at least 10 consecutive business days.
• If not compliant by Jan 19, 2027, may be eligible for additional 180-day grace period if meeting other initial listing standards.
• Company intends to monitor bid price and evaluate options, but no assurance of regaining compliance.